Record sales in April accelerating the pathway to
profitability
New IP will lead the way in changing the way migraine
headaches are addressed
WEST PALM BEACH, Fla.,
April 26, 2024 /PRNewswire/ --
eNeura, a pioneering leader in therapeutic solutions, proudly
announces a monumental milestone in its journey towards
revolutionizing migraine treatment. With unwavering commitment to
innovation and patient well-being, eNeura has already reached
record breaking sales in the month of April experiencing its
highest month of revenue to date raising expectations and
accelerating the timeline forward on profitability thus increasing
eNeura's ability to scale the business much faster than
anticipated.
The remarkable surge in sales and revenue is testament to
eNeura's dedication to meeting the needs of patients suffering from
chronic migraines. This unprecedented achievement reflects not only
the company's financial strength but also its profound impact on
the healthcare landscape. The growing demand has significantly
increased and continues to outpace supply, indicating a pressing
need for accelerated production.
"Our ability to achieve record-breaking sales underscores the
effectiveness and demand for our migraine treatment," said
Teresa Kazaros, Chief Operating
Officer at eNeura. "We are dedicated to scaling our manufacturing
capabilities to meet the overwhelming demand for our devices,
ensuring that we can get them into the hands of patients as swiftly
as possible thus creating an accelerated anticipation that
profitability is not only in the here and now but also sustainable
for the foreseeable future."
Announcement of additional IP
In addition, eNeura announces communication from their IP
counsel of a Notice of Allowance for a new patent on Prophylactic
Treatment of Migraine Headache. This patent further extends the IP
protection for SAVI Dual for an additional 17 years and there are
more patents in process that are meant to further expand the use of
sTMS to treat and prevent migraine that we believe will reset
several of our earlier patents expanding exclusivity for a
significant period of time.
"We have been working diligently on this patent application for
a while and are very excited to finally have it issued," said Dr.
David Rosen, Chairman of eNeura. "We
also have some additional patent applications in process that will
expand the use of sTMS to treat and prevent migraine that we
believe will reset several of our early patents and expand
exclusivity for a significant period."
The outlook for eNeura shines brightly, with a commitment to
providing a safe and effective alternative to traditional migraine
treatment. By offering patients a non-invasive, drug-free option,
eNeura is poised to transform the therapeutic landscape for
migraine sufferers, providing hope and relief while minimizing the
harmful side effects associated with conventional medications.
As eNeura continues to advance its mission of enhancing the
lives of individuals afflicted by chronic migraines, the company
remains steadfast in its commitment to innovation, compassion, and
patient-centric care.
Visit eNeura's website www.eneura.com to learn more about their
groundbreaking solutions revolutionizing the treatment landscape
for migraine and beyond.
Media Contact:
Teresa Kazaros
376695@email4pr.com
561-373-9239
View original content to download
multimedia:https://www.prnewswire.com/news-releases/eneura-achieves-record-breaking-sales-and-announces-notice-of-allowance-for-a-new-patent-on-prophylactic-treatment-of-migraine-headache-302129039.html
SOURCE eNeura